.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10A_InsulinsAndAnalogues.A10AD30_InsulinDegludecAndLiragl.InsulinDegludecAndLiragl .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10A_InsulinsAndAnalogues.A10AD30_InsulinDegludecAndLiragl.InsulinDegludecAndLiragl| name: | InsulinDegludecAndLiraglutide | |
| ATC code: | A10AD30 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 16 | mg |
| volume of distribution: | 0.07 | L |
| clearance: | 0.01 | L/h/kg |
| other parameters in model implementation | ||
This is a fixed-ratio combination of insulin degludec (a long-acting basal insulin analog) and liraglutide (a GLP-1 receptor agonist) used for the treatment of type 2 diabetes mellitus in adults. The combination improves glycemic control with both insulin-dependent and insulin-independent mechanisms. It is approved in many countries and marketed under brand names such as Xultophy.
Pharmacokinetic parameters were studied in healthy subjects and subjects with type 2 diabetes. Parameters below are representative for single-dose administration in adult humans.